Related Experiment Video
Updated: Aug 10, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet agents in coronary artery disease
1Department of Pharmacy Practice, College of Pharmacy, University of Illinois, Chicago 60612.
Clinical Pharmacy
|February 1, 1990
Summary
Antiplatelet drugs, including aspirin, are reviewed for coronary artery disease. While long-term benefits are unclear, aspirin consistently reduces cardiovascular events after infarction, with a daily dose not exceeding 325 mg.
Area of Science:
- Cardiology
- Pharmacology
- Vascular Biology
Background:
- Coronary artery disease (CAD) involves complex pathophysiology and platelet physiology.
- Antiplatelet drugs are crucial in managing CAD, with various mechanisms of action.
Purpose of the Study:
- To review the use of antiplatelet drugs in coronary artery disease.
- To summarize current evidence on the efficacy and risks of antiplatelet therapy in CAD patients.
Main Methods:
- Review of existing literature on antiplatelet agents and their clinical trials in CAD.
- Analysis of studies focusing on aspirin, cyclooxygenase inhibitors, and other antiplatelet mechanisms.
Main Results:
- Aspirin and other nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase, impacting prostaglandin production.
- While primary prevention benefits of aspirin are debated due to stroke risk, secondary prevention consistently reduces nonfatal myocardial infarction and mortality.
- Combination therapy with streptokinase and aspirin showed the greatest mortality reduction in one study.
Conclusions:
- Aspirin, at a daily dose not exceeding 325 mg, improves clinical outcomes in patients with or without prior myocardial infarction or unstable angina.
- Antiplatelet therapy is beneficial for secondary prevention in CAD but should be avoided in patients with high bleeding risk.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...